Total number of publications: 38
2026
-
Development of an integrative cross-omics approach for conceptual adverse outcome pathway network construction
Environment International, year: 2026, volume: 209, edition: March 2026, DOI
2025
-
Correlation of FSTL1 and its paralogs with body composition in adult survivors of childhood cancer
Scientific Reports, year: 2025, volume: 15, edition: 1, DOI
2024
-
Correlating plasma protein profiles with symptomatology and treatment response in acute phase and early remission of major depressive disorder
Frontiers in Psychiatry, year: 2024, volume: 15, edition: September 2024, DOI
-
Endocrine disruption of adipose physiology: Screening in SGBS cells
Journal of Applied Toxicology, year: 2024, volume: 44, edition: 11, DOI
-
Epigenetic and transcriptional control of adipocyte function by centenarian-associated SIRT6 N308K/A313S mutant
CLINICAL EPIGENETICS, year: 2024, volume: 16, edition: 1, DOI
-
Hledání markerů obnovy funkce levé komory s využitím necílené proteomiky: identifikace kandidátních proteinů
Year: 2024, type: Appeared in Conference without Proceedings
-
Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model
CNS NEUROSCIENCE & THERAPEUTICS, year: 2024, volume: 30, edition: 2, DOI
-
Potenciál GLP-1 receptorového agonisty v normalizaci dysmetabolického fenotypu indukovaného olanzapinem o potkana
Year: 2024, type: Appeared in Conference without Proceedings
-
Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model
Biomedicine and Pharmacotherapy, year: 2024, volume: 176, edition: July 2024, DOI
-
Potential of a GLP-1 receptor agonist in normalizing the olanzapine-induced dysmetabolic phenotype in the rat
Year: 2024, type: Appeared in Conference without Proceedings